Abstract
Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue (90)Y-[DOTA](0)-Tyr(3)-octreotide [(90)Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Humans
-
Kidney Diseases / etiology
-
Neuroendocrine Tumors / radiotherapy*
-
Octreotide / adverse effects
-
Octreotide / analogs & derivatives*
-
Octreotide / therapeutic use*
-
Radiation Injuries / etiology
-
Radiopharmaceuticals / adverse effects
-
Radiopharmaceuticals / therapeutic use
-
Radiotherapy / methods*
-
Radiotherapy / trends*
-
Treatment Outcome
-
Yttrium Radioisotopes / adverse effects
-
Yttrium Radioisotopes / therapeutic use*
Substances
-
Radiopharmaceuticals
-
Yttrium Radioisotopes
-
Octreotide
-
Edotreotide